Roche Will Be `Thoughtful' on Regeneron Pricing, CEO Says

The video discusses the intense competition from biosimilars and the impact of COVID-19 on business, highlighting a recovery in the third quarter driven by new medicines and COVID-19 tests. It addresses the challenges faced in healthcare visits and chronic disease treatments due to the pandemic. The development of an antibody cocktail with Regeneron is covered, focusing on approval processes and supply issues. The video concludes with a discussion on supply chain challenges and preparations for Brexit.

What factors contributed to the decline in business during the second quarter?

How did the business recover in the third quarter?

What was the impact of the lockdown on patient behavior regarding doctor visits?

What percentage of capacities have patients returned to in terms of doctor visits?

What is the current status of the antibody cocktail being developed?

What are the plans for ensuring access to the treatment for patients?

How has the company prepared for potential challenges related to Brexit?